Michael Dunne Net Worth

The estimated Net Worth of Michael W. Dunne is at least $1.17 Million dollars as of 6 August 2024. Michael Dunne owns over 106,247 units of Iterum Therapeutics Plc stock worth over $232,101 and over the last 9 years he sold ITRM stock worth over $57,337. In addition, he makes $883,108 as Chief Scientific Officer at Iterum Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Dunne ITRM stock SEC Form 4 insiders trading

Michael has made over 17 trades of the Iterum Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 106,247 units of ITRM stock worth $112,091 on 6 August 2024.

The largest trade he's ever made was exercising 106,247 units of Iterum Therapeutics Plc stock on 6 August 2024 worth over $112,091. On average, Michael trades about 12,139 units every 81 days since 2016. As of 6 August 2024 he still owns at least 220,001 units of Iterum Therapeutics Plc stock.

You can see the complete history of Michael Dunne stock trades at the bottom of the page.

Michael Dunne biography

Dr. Michael W. Dunne M.D. serves as Chief Scientific Officer of the Company. From November 2014 until September 2015, Dr. Dunne was vice president research and development at Actavis. From September 2010 to October 2014, Dr. Dunne served as chief medical officer of Durata Therapeutics, Inc., where he previously served as acting chief medical officer on a consulting basis from December 2009 to September 2010. From 1992 to 2009, Dr.Dunne served in a variety of roles in connection with the clinical development of numerous infectious disease compounds at Pfizer Inc., a biopharmaceutical company, including as the vice president, therapeutic head of development for infectious disease from 2001 to 2009. Dr. Dunne holds a B.A. in economics from Northwestern University and an M.D. from the State University of New York Health Sciences Center. He completed his internal medicine residency and fellowships in infectious diseases and pulmonary medicine at Yale University School of Medicine.

What is the salary of Michael Dunne?

As the Chief Scientific Officer of Iterum Therapeutics Plc, the total compensation of Michael Dunne at Iterum Therapeutics Plc is $883,108. There are 2 executives at Iterum Therapeutics Plc getting paid more, with Corey Fishman having the highest compensation of $1,392,030.

How old is Michael Dunne?

Michael Dunne is 60, he's been the Chief Scientific Officer of Iterum Therapeutics Plc since 2015. There are 1 older and 11 younger executives at Iterum Therapeutics Plc. The oldest executive at Iterum Therapeutics Plc is Dr. Michael W. Dunne M.D., 61, who is the Strategic Advisor & Director.

What's Michael Dunne's mailing address?

Michael's mailing address filed with the SEC is Harcourt Centre, Harcourt St, Saint Kevin's, Dublin 2, Ireland.

Insiders trading at Iterum Therapeutics Plc

Over the last 7 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital... und James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.

What does Iterum Therapeutics Plc do?

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.

Complete history of Michael Dunne stock trades at Iterum Therapeutics Plc

Iterum Therapeutics Plc executives and stock owners

Iterum Therapeutics Plc executives and other stock owners filed with the SEC include:

• Corey Fishman,
  Chief Executive Officer, Director
• Corey N. Fishman,
  Pres, CEO & Director
• Michael Dunne,
  Chief Scientific Officer
• Judith Matthews,
  Chief Financial Officer
• Judith M. Matthews,
  Chief Financial Officer
• Dr. Michael W. Dunne M.D.,
  Strategic Advisor & Director
• Dr. Sailaja Puttagunta M.D.,
  Chief Medical Officer
• Brenton Ahrens,
  Independent Interim Chairman of the board
• Shahzad Malik,
  Independent Director
• David Kelly,
  Independent Director
• Ronald Hunt,
  Independent Director
• Patrick Heron,
  Independent Director
• Mark Chin,
  Independent Director
• Dr. Steven I. Aronin M.D.,
  Sr. VP & Head of Clinical Devel.
• Louise Barrett,
  Sr. VP of Legal Affairs & Sec.
• Tom Loughman Ph.D.,
  Sr. VP of Technical Operations
• Beth Hecht,
  Director
• Vijay K Ratcliffe Liam Lathi,
  
• Venture Partners Ix, L.P.Po...,
  
• James Healy,
  Director
• X L.P.Canaan Partners X Llc...,
  
• Paul R Edick,
  Director
• Jeffrey R. Schaffnit,
  Chief Commercial Officer
• Patrick J Heron,
  Director
• Capital Management, L.P.Ra ...,
  
• Healthcare Vii, L.P.Frazier...,
  
• Venture Partners Ix, L.P.So...,
  
• Venture Partners Ix, L.P.So...,
  
• Alexander J Sarissa Capital...,
  
• Sailaja Puttagunta,
  Chief Medical Officer